Retroperitoneal fibrosis treatment market seen topping $1.04 billion by 2030

The global market for retroperitoneal fibrosis treatment is projected to rise from $0.71 billion in 2026 to $1.04 billion by 2030, driven by autoimmune disease growth, higher healthcare spending and wider use of advanced diagnostics. North America led the market in 2025, while Asia-Pacific is expected to grow fastest.

Why it matters: - The retroperitoneal fibrosis treatment market is moving from a niche rare-disease segment into a faster-growing part of specialty care. - The market’s projected rise to $1.04 billion by 2030 signals stronger demand for imaging, immunosuppressive drugs, biologics and surgical interventions. - Growth in this market reflects broader pressure from autoimmune disease prevalence, aging populations and higher spending on chronic care.

What happened: - The Business Research Company released its Global Retroperitoneal Fibrosis Treatment Global Market Report 2026, covering market size, trends and forecasts through 2035. - The market is forecast to grow from $0.64 billion in 2025 to $0.71 billion in 2026, a 10.0% CAGR. - The market is expected to reach $1.04 billion by 2030, growing at a 10.2% CAGR. - North America was the largest market in 2025. - Asia-Pacific is expected to be the fastest-growing region in the coming years.

The details: - Retroperitoneal fibrosis treatment covers medical and sometimes surgical approaches for a rare condition in which fibrous tissue develops behind the abdominal cavity and can compress the ureters. - Standard treatments include corticosteroids, immunosuppressants and procedures that relieve ureteral compression. - The report points to targeted biologic drugs, AI-powered diagnostic support, minimally invasive treatment options, precision medicine, multidisciplinary care and long-term monitoring as major trends. - The report covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa in addition to North America and Asia-Pacific. - The 2026 reports also include market attractiveness scoring, TAM analysis, company scoring matrix graphics, Excel-based forecasting dashboards, market hotspots infographics and updated graphics and tables. - A free sample is available here. - The full report is available here.

Between the lines: - Autoimmune disease prevalence is a key demand driver because treatment for retroperitoneal fibrosis often centers on suppressing immune-mediated inflammation before fibrotic tissue causes organ damage. - Public Health Scotland said the Scottish Multiple Sclerosis Register recorded 455 new MS cases in 2023, a data point the report uses to illustrate rising autoimmune burden. - The UK Office for National Statistics reported a 5.6% nominal increase in total healthcare expenditure from 2022 to 2023, compared with 0.9% growth in 2022. - The Population Reference Bureau said the number of Americans age 65 and older is projected to rise from 58 million in 2022 to 82 million by 2050, lifting that group’s share of the U.S. population to 23% from 17%. - The market’s momentum suggests more use of specialist centers and longer-term management, not just one-time treatment.

What’s next: - Demand is likely to rise as targeted biologics, AI-supported diagnosis and less invasive procedures become more common. - Market growth should remain tied to earlier diagnosis, better imaging and more personalized immunosuppressive treatment plans. - Long-term monitoring and recurrence prevention are likely to stay central as care models mature.

The bottom line: - Retroperitoneal fibrosis treatment is becoming a faster-growing rare-disease market, with expansion driven by diagnostics, specialty care and rising chronic disease burden.